NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today reported 5 percent revenue growth for the third quarter, with particularly strong growth coming from its Specialty Diagnostics segment, and raised its full-year top- and bottom-line guidance.

The Waltham, Mass.-based provider of labware, research products, and diagnostics reported total revenues of $3.09 billion for the three months ended Sept. 29, up from Q3 2011 revenues of $2.93 billion. It beat analysts' consensus estimate for revenues of $2.99 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.